Scott Eliasof

3.0k total citations · 1 hit paper
47 papers, 2.5k citations indexed

About

Scott Eliasof is a scholar working on Molecular Biology, Cancer Research and Cellular and Molecular Neuroscience. According to data from OpenAlex, Scott Eliasof has authored 47 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 15 papers in Cancer Research and 14 papers in Cellular and Molecular Neuroscience. Recurrent topics in Scott Eliasof's work include Cancer, Hypoxia, and Metabolism (14 papers), Neuroscience and Neuropharmacology Research (13 papers) and Nanoparticle-Based Drug Delivery (8 papers). Scott Eliasof is often cited by papers focused on Cancer, Hypoxia, and Metabolism (14 papers), Neuroscience and Neuropharmacology Research (13 papers) and Nanoparticle-Based Drug Delivery (8 papers). Scott Eliasof collaborates with scholars based in United States, Canada and Taiwan. Scott Eliasof's co-authors include Susan Amara, Michael P. Kavanaugh, Jeffrey L. Arriza, F. Werblin, Craig E. Jahr, Jungyeon Hwang, Barbara H. Leighton, Christian Peters, Douglas Lazarus and Robert S. Kerbel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Scott Eliasof

44 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance

1997 763 citations Jeffrey L. Arriza, Scott Eliasof et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Eliasof United States	23	1.5k	1.4k	365	347	308	47	2.5k
Monique Dontenwill France	32	2.0k 1.4×	857 0.6×	105 0.3×	119 0.3×	49 0.2×	123	3.0k
Sébastien Serres United Kingdom	21	730 0.5×	446 0.3×	61 0.2×	127 0.4×	78 0.3×	30	1.9k
Lydia Danglot France	26	1.3k 0.9×	601 0.4×	250 0.7×	38 0.1×	272 0.9×	52	2.4k
Piera Pasinelli United States	35	2.3k 1.6×	1.3k 0.9×	283 0.8×	252 0.7×	30 0.1×	61	5.7k
Catherine Pan United States	30	1.9k 1.3×	555 0.4×	83 0.2×	42 0.1×	425 1.4×	57	3.9k
Sebastian Munck Belgium	28	1.6k 1.1×	526 0.4×	109 0.3×	49 0.1×	63 0.2×	66	3.0k
Mathew H. Horrocks United Kingdom	27	1.5k 1.0×	457 0.3×	48 0.1×	131 0.4×	90 0.3×	68	3.0k
Leah Boyer United States	15	1.9k 1.3×	1.2k 0.9×	43 0.1×	84 0.2×	57 0.2×	16	3.7k
Yvette C. Wong United States	23	2.3k 1.6×	1.0k 0.7×	106 0.3×	54 0.2×	67 0.2×	32	4.9k
Lawrence J. Hayward United States	36	2.4k 1.7×	777 0.5×	86 0.2×	289 0.8×	121 0.4×	52	4.5k

Countries citing papers authored by Scott Eliasof

Since Specialization

Citations

This map shows the geographic impact of Scott Eliasof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Eliasof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Eliasof more than expected).

Fields of papers citing papers by Scott Eliasof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Eliasof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Eliasof. The network helps show where Scott Eliasof may publish in the future.

Co-authorship network of co-authors of Scott Eliasof

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Eliasof. A scholar is included among the top collaborators of Scott Eliasof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Eliasof. Scott Eliasof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chao, Joseph, James Lin, Paul Frankel, et al.. (2017). Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology. 8(6). 962–969. 24 indexed citations

Pham, Elizabeth, Melissa Yin, Christian Peters, et al.. (2016). Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. Cancer Research. 76(15). 4493–4503. 55 indexed citations

Tian, Xi, Minh Nguyen, Henry P. Foote, et al.. (2016). CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. Cancer Research. 77(1). 112–122. 72 indexed citations

Chao, Joseph, Yi-Chan Lin, Paul Frankel, et al.. (2016). Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC).. Journal of Clinical Oncology. 34(4_suppl). 44–44. 1 indexed citations

O’Keefe, Stephen J., Jean Hoffman‐Censits, Roger B. Cohen, et al.. (2016). Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Annals of Oncology. 27(8). 1579–1585. 47 indexed citations

Wang, Andrew Z., Xi Tian, Minh Nguyen, et al.. (2015). Improving neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, a nanoparticle-drug conjugate, with a camptothecin payload.. Journal of Clinical Oncology. 33(3_suppl). 645–645. 1 indexed citations

Peters, Christian, Douglas Lazarus, Donna M. Brown, et al.. (2015). Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate. Molecular Cancer Therapeutics. 14(12_Supplement_2). B37–B37. 2 indexed citations

Metcalf, Chester A., Donna Brown, Jungyeon Hwang, et al.. (2015). Abstract B176: In vitro and in vivo studies demonstrating sustained drug release for multiple anticancer payloads and improved anticancer effects of a cabazitaxel β-cyclodextrin-PEG copolymer-based nanoparticle-drug conjugate (NDC). Molecular Cancer Therapeutics. 14(12_Supplement_2). B176–B176. 1 indexed citations

Pham, Elizabeth, Michael J. Birrer, Scott Eliasof, et al.. (2014). Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. Clinical Cancer Research. 21(4). 808–818. 77 indexed citations

10.

O’Keefe, Stephen J., Meliessa Hennessy, Ronac Mamtani, et al.. (2014). Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis. Cancer Research. 74(19_Supplement). CT340–CT340. 3 indexed citations

11.

O’Keefe, Stephen J., Daniel F. Heitjan, Amy Marshall, et al.. (2014). Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 412–412. 4 indexed citations

12.

Svenson, Sönke, et al.. (2011). Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. Journal of Controlled Release. 153(1). 49–55. 115 indexed citations

13.

Dunlop, John, Scott Eliasof, Gary Stack, et al.. (2003). WAY‐855 (3‐amino‐tricyclo[2.2.1.0^2.6]heptane‐1,3‐dicarboxylic acid): a novel, EAAT2‐preferring, nonsubstrate inhibitor of high‐affinity glutamate uptake. British Journal of Pharmacology. 140(5). 839–846. 30 indexed citations

14.

Seal, Rebecca P., Yasushi Shigeri, Scott Eliasof, Barbara H. Leighton, & Susan Amara. (2001). Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance. Proceedings of the National Academy of Sciences. 98(26). 15324–15329. 62 indexed citations

15.

Eliasof, Scott, H. Beal McIlvain, Robert E. Petroski, Alan C. Foster, & John Dunlop. (2001). Pharmacological characterization of threo‐3‐methylglutamic acid with excitatory amino acid transporters in native and recombinant systems. Journal of Neurochemistry. 77(2). 550–557. 24 indexed citations

16.

Schwarz, David, Guy Barry, Scott Eliasof, et al.. (2000). Characterization of γ-Aminobutyric Acid Receptor GABAB(1e), a GABAB(1) Splice Variant Encoding a Truncated Receptor. Journal of Biological Chemistry. 275(41). 32174–32181. 88 indexed citations

17.

Eliasof, Scott, Jeffrey L. Arriza, Barbara H. Leighton, Susan Amara, & Michael P. Kavanaugh. (1998). Localization and function of five glutamate transporters cloned from the salamander retina. Vision Research. 38(10). 1443–1454. 55 indexed citations

18.

Arriza, Jeffrey L., Scott Eliasof, Michael P. Kavanaugh, & Susan Amara. (1997). Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proceedings of the National Academy of Sciences. 94(8). 4155–4160. 763 indexed citations breakdown →

19.

Eliasof, Scott & Craig E. Jahr. (1997). Rapid AMPA receptor desensitization in catfish cone horizontal cells. Visual Neuroscience. 14(1). 13–18. 47 indexed citations

20.

Werblin, Frank S., Greg Maguire, Peter D. Lukasiewicz, Scott Eliasof, & Samuel M. Wu. (1988). Neural interactions mediating the detection of motion in the retina of the tiger salamander. Visual Neuroscience. 1(3). 317–329. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact